title: [A CASE OF ADVANCED BLADDER NEUROENDOCRINE CARCINOMA (SMALL CELL CARCINOMA) SIGNIFICANTLY IMPROVED BY LOW DOSE OF ORAL TEGAFUR-URACIL].
abstract: A 81-old-woman underwent a transurethral resection of bladder tumor (TURBT) at a nearby hospital in April 2011. The diagnosis was invasive urothelial carcinoma, G3 with a component of bladder small cell carcinoma, T1 or more. She was recommended to visit our hospital for combined modality therapy of bladder cancer, but she refused the treatment for over one year. In May 2012, she came to our hospital with the chief complaint of pain at urination. Cystoscopy revealed non-papillary sessile tumor in the top of the bladder, and CT scan demonstrated the presence of the right obturator lymph nodes swollen up to 1.2 cm in size. The second TURBT was performed and the diagnosis was bladder small cell carcinoma (pT3N2M0) according to urothelial cancer guidelines of the Japanese Urological Association (JUA). Because she strongly refused hospitalization anymore, we started daily oral intake of low dose Tegafur-Uracil (100 mg) for the treatment. After one month, the serum Neuron-Specific Enolase (NSE; tumor maker of small cell cancer) level was elevated to 27.6 ng/ml and the right obturator lymph node was enlarged up to 1.9 cm. Therefore, the Trgafur-Uracil dose was increased to 200 mg daily. After then, the serum NSE level was decreased to 15.5 ng/ml following reduction in size of the obturator lymph nodes with partial response in December 2013. After two years of follow-up period, her regular urine test showed normal findings, and no apparent recurrence was detected on urinary bladder with MRI and Cystoscopy. This is a case of advanced bladder small cell carcinoma significantly improved by oral administration of Tegafur-Uracil 200 mg/day for over 2 years.
authors.forename: Hayahito
authors.initials: H
authors.lastname: Nomi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Takahara
authors.forename: Koichiro
authors.initials: K
authors.lastname: Minami
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Maenosono
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Yuki
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: Takuya
authors.initials: T
authors.lastname: Tsujino
authors.forename: Hajime
authors.initials: H
authors.lastname: Hirano
authors.forename: Teruo
authors.initials: T
authors.lastname: Inamoto
authors.forename: Ikuhisa
authors.initials: I
authors.lastname: Yamamoto
authors.forename: Motomu
authors.initials: M
authors.lastname: Tsuji
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kiyama
authors.forename: Haruhito
authors.initials: H
authors.lastname: Azuma
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003558:Cystoscopy; D005260:Female; D006801:Humans; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery
chemical_list: D005641:Tegafur; D014498:Uracil